CareFusion Corporation Is Being Investigated on Behalf of Shareholders

Robbins LLP is investigating whether certain officers and directors of CareFusion Corporation (NYSE: CFN) breached their fiduciary duties to shareholders. CareFusion provides healthcare products and services in the United States and internationally.

Robbins Investigates Claims of Improper Marketing of ChloraPrep

Robbins is investigating claims that company officials improperly marketed CareFusion's skin preparation product, ChloraPrep. Specifically, in 2011 the company received subpoenas from the U.S. Department of Justice ("DOJ") and the U.S. Department of Health and Human Services, and in August 2012 the company received a third subpoena from the DOJ. All three subpoenas requested documents and other materials related to the sales and marketing practices for ChloraPrep and information regarding the company's relationships with healthcare professionals. On April 25, 2013, CareFusion announced that it had reached an agreement in principle to resolve three previously disclosed government investigations and will pay $41 million to avoid prosecution and resolve investigations.

Robbins LLP highlights that CareFusion shareholders have the option to pursue a shareholder derivative action through which shareholders aim to hold insider wrongdoers accountable for their actions, prevent future misconduct, and bring long-term value back to the company.

CareFusion shareholders who would like more information about their rights and potential remedies can complete the form below and we will contact you directly. You can also contact attorney Darnell R. Donahue at (800) 350-6003.